Embed Size (px)
Citation preview
Collaborations on Imaging – The Medimmune’s Innovative Way
Jerry Wu, PhD, Medimmune
Developments in Healthcare Imaging – Connecting with Industry 18th October 2017
A brief overview of Medimmune
Scientific collaborations
Scientific Interest Group for Imaging
Contents
2
1
3
2
A brief overview of Medimmune
3
Global Biologics Research and Development Arm of ~2,200
Employees in the US and UK
California Gaithersburg Cambridge
Robust pipeline of 120+ Biologics
in Research & Development with
40+ projects in Clinical Stage
Development
Medimmune – Biologics arm of AstraZeneca
4
GlobalMedicines
Development Market
Innovative Medicines and Early Development Unit(Small Molecules)
MedImmune(Biologics)
Late-stageDevelopment
Discovery and Early Development
Collaboration and combinations
Internal and external opportunities
Current therapeutic areas
5
Biologics Small Molecules Immuno-therapiesProtein
EngineeringDevices
Oncology
Respiratory,
Inflammation and
Autoimmunity
Cardiovascular and
Metabolic Disease Infectious Disease
Main Therapeutic Areas Opportunity-driven
Neuroscience
Medimmune R&D pipeline
6
PHASE 1 PHASE 2 PIVOTAL/PHASE 3PHASE 2
ONCOLOGYRESPIRATORY, INFLAMMATION AND AUTOIMMUNITY
(RIA)
INFECTIOUS DISEASE (ID), NEUROSIENCE AND
GASTROINTESINAL DISEASECARDIOVASCULAR AND METABOLIC DISEASE (CVMD)
MEDI9314Atopic Dermatitis
MEDI-565
Solid Tumors
MEDI0562
Solid Tumors
Durvalumab +
MEDI0562
Solid Tumors
MEDI0680
Solid Tumors
Durvalumab +
TremelimumabSolid Tumors
MEDI9447Solid Tumors
MEDI4920Primary Sjögren’s Syndrome
MEDI1814
Alzheimer’s Disease
MEDI0700Systemic Lupus Erythematosus
AnifrolumabSystemic Lupus Erythematosus
(Subcutaneous)
Durvalumab + IRESSANon-Small Cell Lung Cancer
MEDI1873
Solid Tumors
Durvalumab+
Dabrafenb + TrametinibMelanoma
MEDI8111
Trauma/Bleeding
MEDI4276Solid Tumors
Durvalumab +
MED9447Solid Tumors
Durvalumab +
MonalizumabSolid Tumors
MEDI7352
Osteoarthritis Pain
MEDI9197
Solid Tumors
Durvalumab +
AZD1775Solid Tumors
Durvalumab +
selumetinibSolid Tumors
Durvalumab or Durvalumab +
(Tremelimumab or AZD9150)
Diffuse large B-cell lymphoma
MEDI7734
Myositis
Tremelimumab +
MEDI0562Solid Tumors
MEDI-573Metastatic
Breast Cancer
MEDI8852Influenza A Treatment
MEDI6012Acute Coronary Syndrome
MEDI3902Prevention of Nosocomial
Pseudomonas Pneumonia
Durvalumab
Solid Tumors
InebilizumabNeuromyelitis Optica
AnifrolumabLupus Nephritis
Tezepelumab (MEDI9929)
Asthma/Atopic Dermatitis
Durvalumab/AZD5069/
AZD9150Sq.Cell Carcinoma of H&N
Durvalumab +
TremelimumabGastric Cancer
MavrilimumabRheumatoid Arthritis
MEDI4893Hospital-acquired
Pneumonia / S. aureus
MEDI8897Passive RSV Prophylaxis
MEDI0382Diabetes/Obesity
MEDI4166Diabetes/Cardiovascular
Durvalumab +
MEDI0680Solid Tumors
Durvalumab +
TremelimumabHepatocellular carcinoma
AZD9412Asthma/COPD
MEDI5872Primary Sjögren’s Syndrome
Durvalmab +
Tremelimumab
1st Line NSCLC
Durvalumab
2nd Line SCCHN
Durvalumab +
Tremelimumab
3rd Line NSCLC
Benralizumab
Severe Asthma
Tralokinumab
Severe Asthma
Benralizumab
COPD
Durvalumab +
Tremelimumab
1st Line Bladder Cancer
Durvalumab +
Tremelimumab
1st Line SCCHN
Durvalmab +
Tremelimumab
1st Line NSCLC
Moxetumomab
PasudotoxHairy Cell Leukemia
Durvalumab
≥2nd Line Advanced
Bladder Cancer
Durvalumab
Stage III NSCLC
Anifrolumab
Systemic Lupus Erythematosus
* As of February 2017
Scientific Collaborations
Academic collaboration highlights
8
I N S T I T U T I O N T H E R A P E U T I C A R E A D E S C R I P T I O N
AL L
O N C O L O G Y
AL L
B PD
AL L
AK K
• Joint PhD program supports joint thesis projects • Novel Entrepreneur-in-Residence program• Research collaborations in neuro, biopharmaceutical research
• Creation of CRUK-MEDI Alliance Laboratory• CRUK provides novel drug targets• We provides antibody libraries and antibody engineering technologies
• First industry sponsor for Catalyst awards• Call for proposals in MedImmune therapeutic areas• Goal is to collaborate on joint projects
• Collaborations in formulation science• Multiple projects with joint steering committee
• Research and education collaborations across 4 campuses• Jointly funded with UMB and Maryland Dept. of Business and
Economic Development
• Multiple projects with joint steering committee
In 2015, MedImmune published 550+ publications, in which there were 35+ high impact publications (impact factor > 15)
Scientific collaboration is a key driver behind our move
9
AZ/Medimmune R&D Centre and
Corporate HQ building
Addenbrooke’s Hospital
The Rosie Hospital
School of Clinical
Medicine
Future hospital site
Cambridge Institute
Laboratory of
Molecular Biology
Site of planned Energy Centre
and R&D Enabling Building
Medimmune/AstraZeneca already have >100 collaborations with Cambridge
Key collaborations in Cambridge
10
...through collaborations With the tech and biotech
sector
...through our Scientific Excellence programme
of events
...with leading scientists in Cambridge organisations
LMB / AZ-Medi Blue Sky collaboration
11
LMB Divisions
Cell Biology
Neurobiology
Protein and
Nucleic Acid
Chemistry
Structural
Studies
Core Technology
FacilitiesFrom mass spectrometry and nuclear magnetic resonance to scientific computing
Scientific Interest Group for Imaging
Medimmune Cambridge 2020 Vision
13
Use our unique position and exceptional talent to build scientific
innovation and collaboration to deliver impact for patients
Continuing progress on our 2020 Vision
14
• Collaboration opportunities– Developing externally facing platform to enable future collaboration and
outreach with partners
• Scientific focus – creation of Scientific Interest Groups (SIG)– Imaging
– Machine Learning
– Devices and Delivery
– Genomics
– Experimental Medicine
Scientific Interest Groups – What are they for?
15
• Allow the sharing of ideas & opportunities in distinct focus areas
• Identify opportunities for collaboration within the local area
• Share what is happening within functional & therapeutic areas
• Discuss new technologies and platforms to apply these within the organisation
• A forum to discuss how to solve scientific problems in relevant areas
• Share information & ideas across the organisation –IMED/Medi/Spirogen/Definiens
• Provide a link into the Medimmune 2025 Strategic focus areas
Imaging – part of Digital Health Initiative
16
• Digital pathology – Automated tissue and organ analysis
– Predictive multiplexing IHC biomarkers
– Improve pathology diagnosis through machine learning
• Non invasive techniques– CT, PET and MRI
– In vivo microscopy imaging for expressed biologics
• Image analysis, machine learning and deep learning
Collaboration strategy for Scientific Interest Group
17
• Use networks to uncover partners with technology and capabilities in imaging
– Brainstorm workshop and consult all therapeutic areas
– Internally identify problems that require a solution
– Based on nature of problem, reach out internal and external networks for solutions
• Ultimate goal to access or acquire novel capabilities and technology
How will we work?
18
Work with TAs/
cross functional
groups to identify
the key problems
Reach out for
collaborationsCo-creation of
solution with
external experts
and internal
partners
Evaluate possible
technology to
solve for the
problems
Proof of
concept &
implement
How we achieve our bold vision:
Start Small, Think Big.
19
“Start small, think big. Don’t worry about too many things at once. Take a handful of simple things to begin with, and then progress to more complex ones. Think about not just tomorrow, but the future. Put a ding in the universe.”
Steve Jobs
Our approach to challenges
20
SIG
Imaging
1.
Open Access
2. Efficient
3. Flexible
4. Multi-modal
5. Scalable
6. Maximal Added Value
Acknowledgements
21
• Scientific Interest Group for Imaging
• High Content Imaging at Medimmune Research
• Informatics, Medimmune R&D
• Medimmune Cambridge Site Leadership Team
• AZ High Content Biology & AZ Quantitative Biology
• … and everyone else who helps us do our jobs!
Confidentiality Notice
This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove
it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the
contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus,
Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, www.astrazeneca.com
23
